Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Adhera Therapeutics Inc (ATRX)

Adhera Therapeutics Inc (ATRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 799
  • Shares Outstanding, K 888
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,350 K
  • 60-Month Beta -0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ATRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.57
  • Most Recent Earnings -0.57 on 11/14/22
  • Next Earnings Date 11/28/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6100 +21.31%
on 11/07/22
1.0900 -32.11%
on 11/08/22
+0.1399 (+23.31%)
since 11/04/22
3-Month
0.6001 +23.31%
on 11/04/22
3.0000 -75.33%
on 10/06/22
-0.5080 (-40.71%)
since 09/02/22
52-Week
0.6001 +23.31%
on 11/04/22
3.0000 -75.33%
on 10/06/22
-1.2360 (-62.55%)
since 12/06/21

Most Recent Stories

More News
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Adhera has an exclusive license agreement with Melior Pharmaceuticals I, pursuant to which Adhera is advancing MLR-1023 (tolimidone) into Phase 2 trials...

OTC.VN : 0.400 (-1.23%)
ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update...

ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors

Baton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment...

ATRX : 0.7400 (-17.78%)
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate

Baton Rouge, LA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company...

ATRX : 0.7400 (-17.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.8067
2nd Resistance Point 0.7933
1st Resistance Point 0.7667
Last Price 0.7400
1st Support Level 0.7267
2nd Support Level 0.7133
3rd Support Level 0.6867

See More

52-Week High 3.0000
Fibonacci 61.8% 2.0832
Fibonacci 50% 1.8001
Fibonacci 38.2% 1.5169
Last Price 0.7400
52-Week Low 0.6001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar